共 2 篇相关资讯
资讯首页/标签
Lead report
Co-Diagnostics宣布印度结核病检测产品预计2026年第三季度商业化,同时评估CoSara业务SPAC选项。分析其市场战略前景与投资考量。
Co-Diagnostics announces India tuberculosis test product expected to commercialize in Q3 2026 while evaluating SPAC options for CoSara business. Analysis of market strategy outlook and investment considerations.